UNSPSC 51451908: Oxyclozanide or zanil

This classification denotes an antihelminthic agent with the molecular formula C13H6Cl5NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1QS9G4876X, chemically known as 3,5,6,3,5-pentachloro-2,2-dihydroxybenzanilide but generally known as oxyclozanide, which bears US NIH Compound Identifier 16779. European Medicines Agency schedules Oxyclozanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09561MIG. The term OXYCLOZANIDE is an International Non-Proprietary Name.

OXYCLOZANIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Oxyclozanide or zanil bears US NLM identifiers UMLS ID C0030046 and NCI Concept Code C66279. SMILES: C1=C(C=C(C(=C1CL)O)NC(=O)C2=C(C(=CC(=C2CL)CL)CL)O)CL.

UNSPSC 51451908 Oxyclozanide or zanil is a Commodity code that does not align with recent state and local procurement activity. The two opportunities posted under this code bracket — an Illinois Department of Public Health pharmaceutical warehouse award for Doxycycline Hyclate and Ciprofloxacin Hydrochloride, and a Seminole County, Florida procurement for Naloxone and drug deactivation systems — involve antibiotics, opioid antagonists, and medical devices unrelated to oxyclozanide or zanil. The mismatch between the code's nominal scope and the actual goods being solicited suggests misclassification in the source data rather than active procurement demand for the coded product itself.

The Illinois opportunity, closed as of August 28, 2026, was an Invitation for Bid through the MMCAP Infuse consortium awarding a $2,999,999.11 contract to Chartwell Rx LLC over a three-year term with 12-month renewals. The Seminole County opportunity, posted June 30, 2026 with a July 26, 2026 response deadline, sought 1,900 units of Naloxone and 800 safe drug deactivation systems annually through competitive IFB. Neither opportunity directly reflects procurement activity in the oxyclozanide or zanil product line, and no open solicitations matching the code's stated scope appear in the recent-opportunities block.